ALB and gastric cancer: Meanwhile, those with high NLR/Alb did not have significantly poorer prognoses for the 3Y OS and 3Y RFS rates compared to those with low NLR/Alb in pStage I GC (95.2% vs. 99.0%, p = 0.40 and 94.3% vs. 97.0%, p = 0.69) (Figure S2).